XML 39 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 04, 2025
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
Segment
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Summary Of Significant Accounting Policies [Line Items]                
Cash, cash equivalents and restricted cash, maturity period           three months or less    
Net loss   $ (11,216) $ (6,495) $ (44,907) $ (23,631) $ (17,711) $ (68,538)  
Cash and cash equivalents and short-term investments   107,600       107,600    
Working capital   97,700       97,700    
Accumulated deficit   $ (373,297)       $ (373,297)   $ (355,586)
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]           srt:ChiefExecutiveOfficerMember    
Segment Reporting, Factors Used to Identify Entity's Reportable Segments           The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company’s long-term company-wide strategic goals.    
Number of operating segments | Segment           1    
Number of reportable segments | Segment           1    
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description           the CODM uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results.    
Subsequent event                
Summary Of Significant Accounting Policies [Line Items]                
Percentage of bonus depreciation and domestic research cost 100.00%              
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.                
Summary Of Significant Accounting Policies [Line Items]                
Ownership interest percentage           100.00%    
Otic Pharma, Inc. [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Ownership interest percentage           100.00%